AMNEAL PHARMACEUTICALS INC (AMRX) Stock Price, Forecast & Analysis
USA - NASDAQ:AMRX - US03168L1052 - Common Stock
AMRX Key Statistics, Chart & Performance
The current stock price of AMRX is 11.19 USD. In the past month the price increased by 6.07%. In the past year, price increased by 28.18%.
AMRX Latest News, Press Relases and Analysis
AMRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 40.77 | 848.53B | ||
| JNJ | JOHNSON & JOHNSON | 17.94 | 448.58B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.41 | 253.37B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.84 | 239.77B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.76 | 218.22B | ||
| MRK | MERCK & CO. INC. | 9.36 | 206.04B | ||
| PFE | PFIZER INC | 7.27 | 140.21B | ||
| SNY | SANOFI-ADR | 11.45 | 121.97B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.02 | 93.67B | ||
| GSK | GSK PLC-SPON ADR | 7.64 | 93.22B | ||
| ZTS | ZOETIS INC | 23.21 | 63.97B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 191.71 | 42.38B |
Related stock screener links
About AMRX
Company Profile
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,100 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Company Info
AMNEAL PHARMACEUTICALS INC
400 Crossing Boulevard, 3rd Floor
Bridgewater NEW JERSEY 08807 US
CEO: Chirag Patel
Employees: 8100
Phone: 19089473120
AMNEAL PHARMACEUTICALS INC / AMRX FAQ
What does AMRX do?
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,100 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
What is the stock price of AMNEAL PHARMACEUTICALS INC today?
The current stock price of AMRX is 11.19 USD. The price increased by 3.42% in the last trading session.
Does AMNEAL PHARMACEUTICALS INC pay dividends?
AMRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of AMRX stock?
AMRX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists AMRX stock?
AMRX stock is listed on the Nasdaq exchange.
What do analysts say about AMNEAL PHARMACEUTICALS INC (AMRX) stock?
10 analysts have analysed AMRX and the average price target is 12.24 USD. This implies a price increase of 9.38% is expected in the next year compared to the current price of 11.19.
Should I buy AMRX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AMRX.
AMRX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AMRX. When comparing the yearly performance of all stocks, AMRX is one of the better performing stocks in the market, outperforming 87.29% of all stocks.
AMRX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMRX. AMRX has a medium profitability rating, but doesn't score so well on its financial health evaluation.
AMRX Financial Highlights
Over the last trailing twelve months AMRX reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.12% | ||
| ROA | 0.1% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AMRX Forecast & Estimates
10 analysts have analysed AMRX and the average price target is 12.24 USD. This implies a price increase of 9.38% is expected in the next year compared to the current price of 11.19.
For the next year, analysts expect an EPS growth of 42.89% and a revenue growth 8.95% for AMRX